FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 372 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR K9 Police Officer In Berlin Beats Breast Cancer For Second Time March 7, 2019 Stress-Induced Immune Changes May Help Cancer Spread April 2, 2024 PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based... July 10, 2023 FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... February 4, 2026 Load more HOT NEWS Workout Wednesday – Upper Body Stretches Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in... Opportunity and mentorship: Our new PhD programme aiming to open-up academia...
